Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe

Abstract Background Renal cell carcinoma (RCC) was historically considered to be less responsive to radiation therapy (RT) compared to other cancer indications. However, advancements in precision high-dose radiation delivery through single-fraction and multi-fraction stereotactic ablative radiothera...

Повний опис

Бібліографічні деталі

Автори:	Hari K. Rachamala, Vijay S. Madamsetty, Ramcharan S. Angom, Naga M. Nakka, Shamit Kumar Dutta, Enfeng Wang, Debabrata Mukhopadhyay, Krishnendu Pal
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2024-06-01
Серія:	Journal of Experimental & Clinical Cancer Research
Предмети:	Renal cancer Radiation therapy mTOR Survivin Mitotic catastrophe
Онлайн доступ:	https://doi.org/10.1186/s13046-024-03079-8
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!